Bevacizumab for the treatment of epithelial ovarian cancer: Will this be its finest hour?

Journal of Clinical Oncology

Volumn 25, Issue 33, 2007, Pages 5150-5152

  Kaye, Stanley B ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; DOXORUBICIN; ERLOTINIB; PACLITAXEL; PAZOPANIB; PLACEBO; PLATINUM; SORAFENIB; TOPOTECAN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTERY THROMBOSIS; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; EDITORIAL; EPITHELIUM CELL; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; RISK FACTOR; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 36849083963     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.6150     Document Type: Editorial

References (16)

1. Martin L, Schilder R: Novel approaches in advancing the treatment of epithelial ovarian cancer: The role of angiogenesis inhibition. J Clin Oncol 25:2894-2901, 2007
2. Byrne AT, Ross L, Holash J, et al: VEGF-trap decreases tumor burden, inhibits ascites and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9:571-5728, 2003
3. Alvarez AA, Krigman HR, Whitaker RS, et al: The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 5:587-591, 1999
4. Burger RA, Sill MW, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. J Clin Oncol 25:5165-5171, 2007
5. Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186, 2007
6. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
7. Miller KD: E2100: A phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 3:421-422, 2003
8. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non small cell lung cancer. N Engl J Med 355:2542-2550, 2006
9. Friberg G, Oza AM, Morgan RJ, et al: Bevacizumab (B) plus erlotinib (E) for patients (pts) with recurrent ovarian (OC) and fallopian tube (FT) cancer: Preliminary results of a multi-center phase II trial. J Clin Oncol 24:260s, 2006 (suppl; abstr 5018)
10. Wright JD, Hagemann A, Rader JS, et al: Bevacizumab combination therapy in recurrent platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer 107:83-89, 2006
11. Micha JP, Goldstein BJ, Rettebnauer N, et al: Phase II study of outpatient first-line paclitaxel, carboplatin and bevacizumab for advanced stage epithelial ovarian, peritoneal and fallopian tube cancer. In J Gyn Cancer 17:771-776, 2007
12. Campos S, Dizon D, Cannistra S, et al: Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and mullerian cancers. J Clin Oncol 25:278s, 2007 (suppl; abstr 5517)
13. Azad NS, Annunziata C, Barrett T, et al: Dual targeting of vascular endothelial growth factor with sorafenib and bevacizumab: Clinical and translational results. J Clin Oncol 25:148s, 2007 (suppl; abstr 3542)
14. Tew WP, Colombo N, Ray-Coquard A, et al: VEGF-Trap for patients with recurrent platinum-resistant epithelial ovarian cancer: Preliminary results of a randomized multicentre phase II study. J Clin Oncol 25:276s, 2007 (suppl; abstr 5508)
15. Friedlander M, Hancock KC, Benigno B, et al: Pazopanib is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results in a phase II study. J Clin Oncol 25:289s, 2007 (suppl; abstr 5561)
16. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62, 2005